Global mRNA Synthesis Raw Materials Market Analysis and Forecast

Introduction

The global mRNA synthesis raw materials marketwas valued atUSD 1.73 billion to USD 1.78 billion in 2025 according to top market intelligence firms. The market is projected to reach approximately USD 2.93 billion by 2033, expanding at a stable compound annual growth rate CAGR of 7.10%. Analysis from indicates that nucleotides dominated the 2025 revenue share at 37.56%, with vaccine manufacturing applications capturing the vast majority 83.96% of raw material demand. Geographically, North America holds the largest market share at 36% to 41%, driven heavily by major pharmaceutical and biotech hubs. Meanwhile, broader projections point out that while infectious diseases remain the foundational revenue generator, a definitive pivot toward an oncology pipeline—bolstered by clinical trials for personalized cancer vaccines and a industry-wide demand for certified GMP-grade materials are reshaping the current post-pandemic procurement cycle.

The Global mRNA Vaccine & Therapeutics Raw Material Market is characterized by the presence of a diverse range of biotechnology companies, life science reagent manufacturers, molecular biology solution providers, and advanced chemical suppliers that play a critical role in supporting the development and commercialization of mRNA-based vaccines and therapeutics. Market participants are focused on providing high-quality raw materials, including nucleotides, nucleosides, oligonucleotides, enzymes, plasmid DNA, lipids, molecular biology reagents, protein expression systems, and specialized research chemicals required throughout the mRNA manufacturing process. The growing adoption of mRNA technologies in infectious disease prevention, oncology, rare diseases, and personalized medicine has significantly increased demand for reliable and scalable raw material suppliers.

Leading companies are investing heavily in research and development, advanced manufacturing capabilities, quality assurance systems, and global distribution networks to meet the stringent regulatory requirements of the biopharmaceutical industry. The market is further supported by continuous innovations in synthetic biology, gene synthesis, nucleic acid engineering, RNA technologies, and bioprocessing solutions that enhance the efficiency, stability, and scalability of mRNA production. Companies such as Jena Bioscience, SBS Genetech, Lucigen, and Sigma-Aldrich provide a broad portfolio of critical materials and technologies that support vaccine developers, pharmaceutical companies, research institutions, and contract development and manufacturing organizations (CDMOs) worldwide.

As demand for next-generation vaccines and RNA-based therapeutics continues to rise, market participants are expanding their product portfolios, strengthening strategic partnerships, and increasing production capacities to support global biopharmaceutical innovation. These developments, combined with growing investments in precision medicine, pandemic preparedness, and advanced therapeutics, are expected to strengthen the competitive landscape and drive sustained growth in the Global mRNA Vaccine & Therapeutics Raw Material Market over the coming years.

Market share and revenue analysis

The global mRNA synthesis raw materials market is valued at approximately $1.73 billion to $2.22 billion and is projected to reach up to $3.4 billion by 2034, expanding at a steady compound annual growth rate (CAGR) of 5.4% to 7.1%. Market revenue is heavily segmented by product types and applications, where nucleotides currently command the largest revenue share at over 37% due to high transcription volumes. Meanwhile, lipid nanoparticles (LNPs) represent the fastest-growing component with a 9% CAGR due to advancements in drug delivery systems. While preventive vaccine production historically claims the lion's share of applications at roughly 83%, therapeutics and personalized cancer vaccines are expanding rapidly. Biopharmaceutical companies, contract research organizations (CROs), and contract manufacturing organizations (CMOs) drive the primary end-user demand, with outsourcing growing for early-stage synthesis and scale-up. 

Geographically, North America leads the global landscape with a dominant 36% market share, a position sustained by massive biopharma hubs, regulatory support, and early-adopting research facilities. In contrast, the Asia-Pacific region is emerging as the fastest-growing market, propelled by over $6 billion in localized government funding across nations like China and South Korea to build up domestic, GMP-compliant manufacturing capabilities. The specialized supply chain required for these materials remains consolidated among major life sciences corporations, including Thermo Fisher Scientific, Merck KGaA, TriLink BioTechnologies (Maravai LifeSciences), Aldevron (Danaher), Sartorius AG, and New England Biolabs.

Top Market Players in The Global mRNA Vaccine & Therapeutics Raw Material Market

Jena Bioscience GmbH

Jena Biosciences GmbH was founded in 1998 and is headquartered in Jena, Germany and is part of the other chemical product and preparation manufacturing industry. The company offers its products in the categories include nucleotides & nucleosides, chemistry, molecular biology, LEXSY expression, proteins, crystallography & cryo-EM, probes & epigenetics, and RNA technologies. The company has a team of scientists from the Max-Planck-Institute of Molecular Physiology (Dortmund), Jena Bioscience utilizes more than 25 years of academic know-how to develop innovative reagents for clients from both research and industry in 100+ countries. Jena Bioscience remains an owner-operated business. They manufacture in Germany according to international standards of DIN EN ISO 9001 (since 2008) & DIN EN ISO 14001 (since 2015). The company is working with the offices worldwide. Jena Bioscience serves three major client groups which include research laboratories at universities, industry, government, hospitals and medical schools and pharmaceutical industry in the process from lead discovery through to pre-clinical stages as well as laboratory & diagnostic reagent kit producers and re-sellers. In its chemistry division, they have hundreds of nucleotides in stock. With in-house expertise manufacture even the most exotic nucleotide analog from mg to kg scale. Further, the company offers innovative reagents for functionalization, conjugation and labeling of (bio) molecules as well as a toolbox for synthesis, labeling, modification, analysis and detection of RNAs, complemented by custom specific services. In the field of recombinant protein production, Jena Bioscience has developed its proprietary LEXSY (Leishmania Expression System) technology. It is specialized reagents for protein stabilization, crystal screening, crystal optimization, and phasing. In the field of molecular biology, it offers a large selection of single reagents, complete kits and optimized master mixes. This section includes products for DNA or RNA purification, amplification and modification with focus on PCR-related techniques. The company is engaged in manufacturing, sales, service and research and development (R&D) globally. Jena Biosciences GmbH customers has its production facilities in Europe, Asia and America as well as sales subsidiaries and local commercial agencies in more than 100+ countries. The company has evolved into an established global reagent supplier with about 8000 products in stock. Jena Bioscience remains an owner-operated business. They manufacture in Germany according to international standards of DIN EN Jena Bioscience GmbH has 34 employees at this location.

SBS Genetech

SBS Genetech is a Chinese organization provides scientific solutions for biological researchers and scientists, beginning from custom oligonucleotides combination, gene synthesis and custom peptide synthesis. It was founded in 2000, and headquarter is based in Beijing, Haidian and is one of the country's leading biotechnology company. SBS Genetech not just offers custom oligos, gene synthesis, and peptide synthesis services likewise offer the accompanying items: DNA synthesis items, DNA atomic weight markers, nucleic acids isolation and purification kits, PCR-related products, gene manipulation products, isothermal amplification products and gene manipulation products. With its momentous attributes, company has obtained a main position in such fields and added to life science advancement along with brilliant scientists. Huge number of papers has been distributed on the planet's academic journals with company’s products. Over many years, by giving more secure, better quality, and more reasonable products, company have served top scientists in almost 60 nations, enabling them to make new central information in the area of biology. The company has 51-200 employees around the world.

Lucigen

Lucigen was founded in 1998 and is headquartered in Middleton, Wisconsin, U.S. The company manufactures and sells over 325 biomedical research products to life-science and healthcare professionals worldwide. Lucigen leverages its expertise in enzyme evolution and core competencies that support a variety of applications such as synthetic biology, next gen sequencing, and human diagnostics. Lucigen’s acquisition of Epicentre products expanded company’s portfolio offering into array-based analysis, in vitro transcription, nucleic-acid extraction purification, and transposon mutagenesis. The company’s major product categories include cloning kits & vectors, in vitro transcription, competent cells, next generation sequencing, nucleic acid extraction and purification, protein expression and transposon mutagenesis. The company has received ISO 13485-certification. The company offers solutions to meet researchers’ expanding needs, including OEM partnerships. The company has more than 200 employees working in the office. The company distributes its products in North America, Latin America, Europe, Middle East and Africa, Asia Pacific and China.

Sigma Aldrich

Sigma Aldrich was founded in 1975 and is headquartered at St. Louis, Missouri, United States. Sigma-Aldrich operates as a life science and technology material company. It develops, manufactures, purchases and distributes a broad range of biochemical and organic chemicals. Sigma-Aldrich became a subsidiary of Merck KGaA in 2015. Sigma-Aldrich’s biochemical and organic chemical products are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The company operates through four research business units: essentials, specialties, biotech and SAFC. The research essentials unit sells biological buffers, cell culture reagents, biochemical, chemicals, solvents, and other reagents and kits. The research specialties unit sells organic chemicals, biochemical, analytical reagents, chromatography and other laboratory consumables, reference materials and high-purity products which are generally sold in smaller volumes to the lab scientist customer. The research biotech unit supplies immunochemical, molecular biology, cell biology, proteomic, genomic, transgenic and other life science products to academic, government, industrial, biotechnology and pharmaceutical research customers. The SAFC unit supplies large-scale organic chemicals and biochemical used in development and production by pharmaceutical, biotechnology, industrial, diagnostic and electronics companies. The company has a broad global customer base, which includes commercial laboratories, pharmaceutical, industrial, diagnostics, biotechnology and electronics companies, universities, hospitals, governmental institutions and other non-profit organizations. Sigma-Aldrich is the world’s largest supplier of research biochemical and organic chemicals. Every day more than one million customers around the globe count on Sigma-Aldrich for quality products delivered on time and as promised. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university, and government institutions, hospitals, and industry. Sigma offers more than 300,000 products. The company has 22,000 employees, presence in 66 countries, 130 distribution centers and 60 manufacturing sites.

mRNA Vaccines And Therapeutics Market

MRNA Vaccine & Therapeutics Raw Material Market

Synthetic mRNA Market

Synthetic mRNA Market for Cancer Treatment